Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Compatible with any colonoscope video, the module provides physicians with a powerful tool in the fight against colorectal cancer — the third most common form of cancer in Canada with 26,300 cases diagnosed in 2019. i

"More than a million screening colonoscopies are performed in Canada each year. The integration of leading-edge technologies such as AI into gastroenterology practices is very exciting," said Dr. Clarence Wong , section chief, gastroenterology, Alberta Health Services, Edmonton Zone. "It could be a key factor in the prevention of colorectal cancer."

The GI Genius module uses advanced AI to highlight the presence of possible precancerous lesions with a visual marker in real-time. The colonoscopy images are processed using advanced algorithms that can identify and mark polyp abnormalities, including those that could otherwise go undetected by the human eye.

Acting as a second observer, the GI Genius module helps increase the adenoma detection rate (ADR). Studies show that every 1% increase in ADR reduces the risk of colorectal cancer by 3%. ii,iii The flexibility of this platform means it can be seamlessly integrated into different clinical workflows, enabling clinical decision making, and increasing quality of care by reducing variability.

"Detection of colonic adenomatous polyps during colonoscopy is an important quality metric," said Dr. Wong. "The addition of AI to help improve adenoma detection rates can increase the quality of colonoscopies, potentially improving diagnosis and outcomes for colon cancer patients."

Use of the GI Genius module in studies has resulted in a 14% absolute increase in ADR compared to colonoscopy alone for both flat (42% increase) and polyploid (36% increase) lesions, demonstrating increasing accuracy to help reduce the rise of interval cancers occurring between colonoscopies. iv

"Medtronic is committed to helping to improve outcomes for patients with colon cancer," said Neil Fraser , president of Medtronic Canada. "GI Genius is currently the only colonoscope-agnostic AI platform designed to enhance polyp detection. Simply put, this technology will help save lives by improving colon cancer detection rates."

Medtronic is the exclusive worldwide distributor of the GI Genius module, which was developed and is manufactured by Cosmo Pharmaceuticals.

Learn more at Medtronic.ca/gigenius

About Medtronic Canada ULC
Bold thinking. Bolder actions. We are Medtronic.  Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC is headquartered in Brampton, Ontario , with regional offices in Montreal and Vancouver , and is a subsidiary of Medtronic plc. We are the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Our technologies and therapies address 70 health conditions and include cardiac devices, cranial and spinal robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

For more information on Medtronic Canada, visit www.Medtronic.ca and follow @MedtronicCa on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

__________

i

Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019.
Available at: cancer.ca/Canadian-Cancer-Statistics-2019-EN]. Accessed May 2021.

ii

Wang P, Berzin TM, Glissen Brown JR , et al. Gut 2019; 68:1813-1819.

iii

Corley DA, Jenson CD, Marks AR JR, et al. NEJM 2014;370:1298-306.

iv

Repici, A., Badalamenti, M., Maselli, R., et al. Gastroenterology 2020; doi: https://doi.org/10.1053/j.gastro.2020.04.062 .

SOURCE Medtronic Canada ULC

View original content to download multimedia: https://www.newswire.ca/en/releases/archive/November2021/30/c3856.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Thermo Fisher Scientific Elects New Director to Board

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment brings the total number of Thermo Fisher board members to 12.

Ms. Lynch is a seasoned health care executive with over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS), a leading health solutions company, she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits management businesses, and presence in over 9,000 community health destinations across the U.S. Prior to her service as president and CEO of CVS Health, Ms. Lynch served as an Executive Vice President of CVS Health and President of Aetna, and prior to that, Ms. Lynch held a number of executive positions at Aetna Inc., a health insurance company, Magellan Health Services, a health care management company, and at Cigna Corporation, a global health insurance company. Ms. Lynch began her career as a Certified Public Accountant at the auditing firm Ernst & Young LLP, and has previously served as a board member of CVS Health and U.S. Bancorp.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2025 financial results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2025 financial results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2025 financial results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2025 financial results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2025 financial results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×